Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics (Nasdaq: HRTX) has rescheduled its second quarter 2025 financial results release and conference call to Friday, August 8, 2025, at 8:30 a.m. ET, moved up from the previously scheduled date of August 11, 2025.
The company will discuss Q2 2025 financial results and recent business highlights during the call. Participants are encouraged to dial in fifteen minutes before the start time using the provided registration link. The presentation will also be available via webcast on Heron's website, with a replay accessible for 60 days following the call.
Heron Therapeutics (Nasdaq: HRTX) ha anticipato la pubblicazione dei risultati finanziari del secondo trimestre 2025 e la conference call al venerdì 8 agosto 2025, alle 8:30 ET, rispetto alla data precedentemente fissata per l'11 agosto 2025.
Durante la chiamata, l'azienda discuterà i risultati finanziari del Q2 2025 e gli ultimi sviluppi aziendali. Si consiglia ai partecipanti di collegarsi quindici minuti prima dell'inizio utilizzando il link di registrazione fornito. La presentazione sarà inoltre disponibile in webcast sul sito di Heron, con la possibilità di rivederla per 60 giorni dopo la chiamata.
Heron Therapeutics (Nasdaq: HRTX) ha adelantado la publicación de los resultados financieros del segundo trimestre de 2025 y la conferencia telefónica al viernes 8 de agosto de 2025 a las 8:30 a.m. ET, en lugar de la fecha previamente programada para el 11 de agosto de 2025.
Durante la llamada, la compañía discutirá los resultados financieros del segundo trimestre de 2025 y los recientes aspectos destacados del negocio. Se recomienda a los participantes que se conecten quince minutos antes del inicio utilizando el enlace de registro proporcionado. La presentación también estará disponible por webcast en el sitio web de Heron, con una repetición accesible durante 60 días después de la llamada.
Heron Therapeutics (나스닥: HRTX)는 2025년 2분기 재무실적 발표 및 컨퍼런스 콜을 기존 예정일인 2025년 8월 11일에서 2025년 8월 8일 금요일 오전 8시 30분(동부 시간)으로 앞당겼습니다.
이번 콜에서는 2025년 2분기 재무실적과 최근 사업 주요 내용을 논의할 예정입니다. 참가자들은 제공된 등록 링크를 통해 시작 15분 전에 접속할 것을 권장합니다. 발표 내용은 Heron 웹사이트를 통해 웹캐스트로도 제공되며, 콜 후 60일간 다시보기 가능합니다.
Heron Therapeutics (Nasdaq : HRTX) a avancé la publication de ses résultats financiers du deuxième trimestre 2025 et la conférence téléphonique au vendredi 8 août 2025 à 8h30 ET, au lieu de la date initialement prévue du 11 août 2025.
Lors de l'appel, la société discutera des résultats financiers du T2 2025 ainsi que des faits marquants récents. Les participants sont invités à se connecter quinze minutes avant le début via le lien d'inscription fourni. La présentation sera également disponible en webcast sur le site de Heron, avec un replay accessible pendant 60 jours après l'appel.
Heron Therapeutics (Nasdaq: HRTX) hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 und die Telefonkonferenz auf Freitag, den 8. August 2025, um 8:30 Uhr ET vorverlegt, ursprünglich war der 11. August 2025 geplant.
Das Unternehmen wird während des Calls die Finanzergebnisse des zweiten Quartals 2025 sowie aktuelle Geschäftshighlights besprechen. Die Teilnehmer werden gebeten, sich fünfzehn Minuten vor Beginn über den bereitgestellten Registrierungslink einzuwählen. Die Präsentation wird auch per Webcast auf der Heron-Website verfügbar sein, mit einer Wiedergabe, die 60 Tage nach dem Call abrufbar ist.
- None.
- None.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-reschedules-second-quarter-2025-earnings-release-and-conference-call-to-friday-august-8-2025-302525007.html
SOURCE Heron Therapeutics, Inc.
FAQ
When is Heron Therapeutics (HRTX) reporting Q2 2025 earnings?
How can investors access Heron Therapeutics' Q2 2025 earnings call?
How long will the replay of Heron Therapeutics' Q2 2025 earnings call be available?
Why did Heron Therapeutics reschedule its Q2 2025 earnings call?
